logo

Soligenix, Inc. (SNGX)



Trade SNGX now with
  Date
  Headline
4/6/2020 7:07:12 AM Soligenix Receives European Patent For Therapeutic Use Of Synthetic Hypericin To Treat Cutaneous T-Cell Lymphoma
3/30/2020 7:11:59 AM Soligenix FY Net Loss $9.4 Mln Or $0.48/Shr Vs Loss $8.9 Mln Or $0.68/Shr Last Year
3/23/2020 7:06:25 AM Soligenix And University Of Hawai?i At Manoa Initiate Work On Novel Coronavirus Vaccine For COVID-19
3/19/2020 6:01:54 AM Soligenix Announces Positive Top-line Results For Pivotal Phase 3 FLASH Trial Evaluating SGX301
2/13/2020 8:12:04 AM Soligenix FDA Grants Fast Track Designation For RiVax In Prevention Of Ricin Poisoning
2/3/2020 7:02:22 AM Soligenix Announces Japanese Patent Allowance For Use Of Dusquetide In Oral Mucositis
12/18/2019 7:03:29 AM Soligenix To Get $850K In Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
12/12/2019 7:18:26 AM Soligenix Initiates Phase 1C, Double-Blind, Placebo-Controlled, Randomized Study To Evaluate The Safety Of RiVax
12/3/2019 7:08:33 AM Soligenix Completes Enrollment In Its Pivotal Phase 3 Clinical Trial Of SGX301 In Treatment Of Cutaneous T-cell Lymphoma
11/12/2019 7:15:13 AM Soligenix Q3 Net Loss $2.7 Mln Vs. Net Loss $1.9 Mln Last Year
9/16/2019 7:03:11 AM Soligenix Appoints Daniel Ring As VP Of Business Development And Strategic Planning
9/11/2019 7:02:19 AM Soligenix Appoints Jonathan Guarino As SVP And CFO
  
 
>